Back to results
US 2026/0218128 A1Published application
Nkg2d engineered cell and composition thereof
AssigneeCarsgen Life Sciences Co., Ltd.
InventorsZonghai LI, Hua JIANG, Yi WANG, Yu ZHANG, Liang ZHOU
Life of this patent
Estimating the term…
Abstract
An engineered immune cell for use in immunotherapy and a preparation method therefor. The engineered immune cell is more persistent in a host organism and has a high transplantation survival rate.
Claims21
1-87. (canceled)
An engineered cell targeting allogeneic immune cells, wherein the engineered cell expresses a molecule that recognizes a NKG2D ligand, and the expression of the molecule that recognizes the NKG2D ligand is regulatable.
An antibody recognizing myelin oligodendrocyte glycoprotein (MOG), wherein the antibody is selected from the group consisting of:
- (1) an antibody, comprising a light chain variable domain, wherein the light chain variable domain comprises LCDR1 represented by SEQ ID NO:
- 84, and/or LCDR2 represented by SEQ ID NO:
- 85, and/or LCDR3 represented by any one of SEQ ID NO:
- 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97 or 98;
- (2) an antibody, comprising a heavy chain variable domain, wherein the heavy chain variable domain comprises HCDR1 represented by SEQ ID NO:
- 99 or 100, and/or HCDR2 represented by SEQ ID NO:
- 101 or 102, and/or HCDR3 represented by any one of SEQ ID NO:
- 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115;
- (3) an antibody, comprising the light chain variable domain of the antibody described in (1) and the heavy chain variable domain of the antibody described in (2);
- and
- (4) an antibody, which is a variant of the antibody of any one of (1)-(3), and has the same or similar activity as the antibody of any one of (1)-(3);
- optionally, the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprised by the antibody are respectively selected from:
- (1) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 86, 99, 101, and 103;
- or
- (2) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 87, 99, 101, and 104;
- or
- (3) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 88, 99, 101, and 105;
- or
- (4) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 89, 99, 101, and 106;
- or
- (5) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 90, 99, 101, and 107;
- or
- (6) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 91, 100, 102, and 108;
- or
- (7) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 92, 100, 102, and 109;
- or
- (8) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 93, 100, 102, and 110;
- or
- (9) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 94, 100, 102, and 111;
- or
- (10) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 95, 100, 102, and 112;
- or
- (11) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 96, 100, 102, and 113;
- or
- (12) the amino acid sequences represented by SEQ ID NO:
- 84, 85, 97, 100, 102, and 114;
- or
- (13) the amino acid sequences represented by SEQ ID NOs:
- 84, 85, 98, 100, 102, and 115.
47 more elements
Dependencies are inferred from the claim text.